Oxford Nanopore raises £29.3m in Series H+ funding and £80.2m in secondary share sales.
The company secured new capital from international investors across the US, Europe, and Asia.
Oxford Nanopore Technologies develops DNA and RNA sequencing solutions used across scientific research and public health applications. Founded in 2005 as a spin-out from the University of Oxford, the business provides technology to characterise pathogens and advance biomedical science.
Oxford Nanopore Technologies has secured £29.3m in a Series H+ investment round alongside a £80.2m secondary share sale. The capital was gathered from international backers spanning the US, Europe, and Asia, involving both new participants and existing shareholders. This transaction brings the firm total primary investment to approximately £480m.
Categories
About the company
Oxford Nanopore Technologies
Oxford Nanopore Technologies develops DNA and RNA sequencing systems for scientific research and public health.